Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Refractory/Relapse Neuroblastoma 1Papillomavirus Infections 1Osteoporosis 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Infertility 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Hodgkin Disease 1High Grade Cervical Intraepithelial Neoplasia 1Esophageal Neoplasms 1Burkitt Lymphoma 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Biological Products × Clear all
NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Cancer Research UK

Phase 1/2 Suspended
15 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
127 enrolled
BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡